When we talk about blood cancers, we mean malignancies that occur in the bone marrow, blood and lymphatic system. In this article, different types of blood cancers are introduced, then we will express the survival rate of patients with any type of blood cancer. First of all, it is better to introduce the types of blood cancers

what you will read next :


Types of blood cancers

Blood cancers are divided into the following three main groups:


  1. The first group of leukemias:

Involves blood and bone marrow Leukemia can be acute or chronic.

They can affect a group of blood and bone marrow cells called the lymphocyte family (called the lymphoid group). The following two types of leukemia are malignant types of the lymphoid family:

leukemia can also affect a group of blood and bone marrow cells called the myeloid group.

The following two types of leukemia are caused by malignancy of the myeloid group of cells:


  1. The second group of lymphomas

Involve parts of the immune system and a group of defense white blood cells called lymphocytes.

Lymphomas are divided into the following two main categories:


  1. The third group of myeloma

This type of blood cancer develops in a type of white blood cell called plasma cells.

Types of myeloma


What is meant by survival rate?

It is a statistical measurement in medicine, which states the percentage of people with a particular type of disease or cancer, for example, have survived up to five years after being diagnosed with the disease.

For example, we say that the five-year Survival Rate of x-cancer is twenty-five percent, meaning that twenty-five percent of people with x-cancer survive five years after diagnosis.

Now we will answer the following question

What is the survival rate of blood cancer?

About ninety percent of all children with ALL recover with treatment. Five-year survival in remission children with ALL is eighty to eighty-five percent.

In seventy-five to ninety percent of adults with ALL with complete treatment, remission occurs, meaning that the cancer cells are no longer seen in their blood, but unfortunately fifty percent of these remissions recur.

Three-year survival in adults with ALL with treatment is twenty-five to fifty percent

Survival of adults with ALL without treatment will unfortunately only be a few months.

Five-year survival in people with ALL according to age is:

People equal and older than twenty: thirty-seven percent

People under the age of twenty: Eighty-nine percent of

Seventy percent of people, regardless of age, survive five years of treatment

Survival depends on a variety of factors in addition to age

Survival in this leukemia depends on the stage of the person. In general, the five-year survival of patients with CLL who are over twenty years old is about eighty-five percent.

There is no cure for leukemia, but most people with CLL live for years. Many people can survive for years without treatment, but most people get treatment.

The ten-year survival of patients with treatment will be between fifty-five to sixty-five percent. One-third of patients with CLL survive 10 to 20 years after the time of diagnosis with treatment.

Survival in this type of leukemia depends on the exact type of leukemia. Without treatment, survival will be about days or months. Up to 70% of patients will enter the remission phase with treatment. Remission phase means that there will be no cancer cells in their bone marrow, people over the age of sixty will respond poorly to treatment.

The five-year survival of patients with AML with treatment, according to the age distribution, is as follows:

Most of these people will survive five years after the diagnosis of leukemia with treatment. With imatinib, 90% of patients have a five-year survival. Without treatment, the leukemia will enter the excretory phase. The five-year survival rate with treatment in all age groups according to Age is:

Survival Wright Lymphoma Hodgkin:

Five-year survival : 87%

If cancer is detected in the early stages, the five-year survival will be ninety-two percent.

Hodgkin’s lymphoma localized: five-year survival of ninety-two percent

Regional: Ninety-four percent

Hodgkin’s lymphoma progresses to other tissues: seventy-eight percent

And the overall five-year survival of Hodgkin’s lymphoma since diagnosis is about eighty-seven percent. Without treatment, the average survival rate will be about 6.16 months. Three-year survival without treatment approx. 4.15 and a five-year survival without treatment is less than six percent


Hodgkin’s stage and type of lymphoma are important for survival. With treatment, the five-year survival of all Hodgkin’s lymphomas is about seventy-two percent.

With treatment, the five-year survival on stage 1 of non-Hodgkin’s lymphoma is more than 82%.

Stage Two is about seventy-five percent

Stage three seventy percent

In recent years, with the advancement of treatment, about fifty to sixty percent of patients with non-Hodgkin’s lymphoma remain without recurrence for up to five years.

The person may remain asymptomatic for years. After five to ten years, when non-Hodgkin’s lymphoma develops rapidly, the bone marrow becomes inadequate to produce blood cells, and the person becomes infected, anemic, and bleeds and eventually dies.


Survival in multiple myeloma is as follows:

Multiple myeloma is sometimes difficult to diagnose in the early stages and is usually diagnosed when the cancer has advanced.

The overall five-year survival rate for about 5 percent of people at each stage of multiple myeloma is about 71 percent.

Survival on the stage1 of a multiple myeloma with treatment: 4 months

Survival on stage2 :44 months

Sometimes a number of patients survive for ten to twenty years with treatment

The three-year survival in patients at all stages is about sixty percent

Five-year survival in 5% of patients with multiple myeloma diagnosed in the early stages with treatment: 74%

Five-year survival in cases where multiple myeloma has spread to other parts of the body is 51% with treatment.

According to the latest study conducted in May2020. The survival of patients with multiple myeloma is as follows: